Shilpa Medicare on Monday said it has received approval from the US health regulator for Gemcitabine for injection, used for treatment of various types of cancers.
The approved product is a generic equivalent of reference listed drug Gemzar.
The company has received United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection USP in the strengths of 200 mg/vial and 1 g/vial, Shilpa Medicare said in a Bombay Stock Exchange (BSE) filing.
Gemcitabine for injection USP is used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and pancreatic cancer.
Quoting IQVIA MAT data for December 2018, Shilpa Medicare said, the US market for Gemcitabine for injection USP, 200 mg/vial and 1 g/vlal is approximately $11.7 million.
Shares of Shilpa Medicare were trading 2.19 per cent up at Rs 359 apiece on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.